KEY POINTS
- OPTNT (NCT05563922) was a prospective, single-center, nonrandomized phase II trial conducted at Fudan University, Shanghai, evaluating total neoadjuvant therapy followed by planned local excision for selected cT1–3N0M0 nonmucinous low rectal adenocarcinomas within 5 cm of the anal verge. Between June 2022 and March 2024, 60 patients entered screening/enrollment and 57 formed the modified intention-to-treat population; 78.9% had cT3 disease, and 78.9% had tumors within 3 cm of the anal verge.
- Treatment consisted of 45 Gy in 25 fractions to the pelvis with a simultaneous boost to 50 Gy, combined with two cycles of CAPOX, followed by four consolidation CAPOX cycles. Clinical response was assessed approximately 12 weeks after radiotherapy using MRI, endoscopy, biopsy, digital rectal examination, and CEA. Patients with complete or near-complete clinical response were offered local excision; incomplete responders or those with high-risk pathology after excision were directed toward total mesorectal excision (TME).
- Clinical complete response occurred in 47.4% and near-complete response in 38.6%, yielding 86.0% (49/57) with either response category after neoadjuvant therapy. Among 51 surgically treated patients, pathological complete response was 68.6% (35/51). Using all 57 patients as the denominator and counting watch-and-wait patients as non-pCR, the pathological complete response rate was 61.4%, while the combined complete response endpoint reached 68.4% (39/57).
- Among 40 patients undergoing local excision, 29 (72.5%) achieved pathological complete response, while seven (17.5%) had high-risk residual disease. Ultimately, 35 patients underwent local excision alone, five required completion TME, and 11 underwent upfront TME. Overall sphincter preservation was 94.7% (54/57), although this is distinct from the protocol's primary endpoint of sustained organ preservation without TME.
- The local-excision pathway showed favorable short-term surgical and functional outcomes compared with TME. Median blood loss was 7 versus 50 mL (p<0.001), and median hospitalization was 7 versus 14 days (p=0.001). At six months, 80.0% of local-excision patients versus 53.8% of TME patients reported no low anterior resection syndrome, while major LARS occurred in 5.7% versus 46.2% (exploratory p=0.027); these comparisons were nonrandomized and vulnerable to response-based selection.
- Grade 3 treatment-related adverse events occurred in 22.8%, predominantly lymphocytopenia, with no grade 4 or 5 events. One patient discontinued capecitabine because of grade 3 diarrhea. Major postoperative complications occurred in 1/35 patients (2.9%) undergoing local excision alone and 1/11 (9.0%) undergoing upfront TME, although these small groups do not allow meaningful comparative safety conclusions.
- The study's primary endpoint is three-year organ preservation without TME, which was not reported in this short-term analysis. Median follow-up was 28 months, and mature locoregional recurrence, distant metastasis, event-free survival, and overall survival results were unavailable. Patient preference influenced treatment allocation, and neither the local-excision strategy nor its functional outcomes were randomized against watch-and-wait or standard TME.
CLINICAL TAKEAWAY
Total neoadjuvant therapy followed by selective local excision produced high pathological response rates and encouraging early sphincter-preservation outcomes in carefully selected patients with low rectal cancer. However, the nonrandomized treatment pathway and absence of mature three-year organ-preservation and oncological endpoints prevent conclusions that planned excision is superior to watch-and-wait or standard surgery.
SOURCE
International Journal of Radiation Oncology, Biology, Physics